| Date | Title | Description |
| 05.09.2024 | Health | The technology used to make the COVID vaccine may be key to pancreatic cancer treatment | Once removed, the tumor is sent to a company in Europe, Genentech, which will perform DNA sequencing on the tumor to create an individualized vaccine for each patient. If effective, the vaccine will lessen the recurrence of pancreatic cance... |
| 29.08.2024 | Navigating the New Normal: COVID Vaccines and Creative Leadership in Healthcare | The landscape of healthcare marketing is shifting. Imre, a prominent brand engagement agency, has made significant strides by appointing Tracy Zuto and Malia Baker as key creative leaders. Their arrival signals a commitment to innovative, i... |
| 28.08.2024 | Imre announced two new appointments to Strengthen Brand AOR Expertise | Imre continues its commitment to cutting-edge creative that builds brand engagement with the appointment of two senior creative leaders, as the agency strengthens its position as a distinct choice for agency-of-record assignments in healthc... |
| 27.08.2024 | Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH | With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregiversApproval is based on COMMODORE 2, where subcutane... |
| 27.08.2024 | Imre Appoints Powerhouse Leaders Tracy Zuto and Malia Baker and Strengthens Brand AOR Expertise | New Additions Reflect Commitment to Creative Excellence and Healthcare Industry Leadership
NEW YORK, Aug. 27, 2024 /PRNewswire/ -- Imre continues its commitment to cutting-edge creative that builds brand engagement with the appointment of t... |
| 27.08.2024 | ArkBio Presented at the 8th Annual IPF Summit and Announced Completion of Patient Enrollment for Phase 2 Clinical Trial of AK3280, a Next-Generation Drug for IPF Treatment | BEIJING, Aug. 27, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a privately held, clinical-stage biopharmaceutical company today announced that Dr. Jim Wu, Chief Executive Officer of ArkBio, gave an ora... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 21.08.2024 | Innovations in Financial Planning: A New Era for Later Life Management | In the world of finance, innovation is the lifeblood that keeps the industry vibrant. Recently, two companies emerged as champions in the Later Life Financial Planning Innovation Challenge, hosted by Smart Data Foundry and FinTech Scotland.... |
| 20.08.2024 | REPUBLICA HAVAS EXPANDS NORTH AMERICAN FOOTPRINT WITH THREE APPOINTMENTS | A trio of executives has been appointed to lead the agency's expansion into New York City
NEW YORK, Aug. 20, 2024 /PRNewswire/ - Republica Havas announced today the appointments of three executives to lead the agency's continued expansion i... |
| 17.08.2024 | KNIME: Open-Source Data Science And AI Company Raises $30 Million | KNIME, one of the leading open-source data science and AI companies, announced it has raised additional funding from its longstanding investor, Invus. Since the last announcement, Invus has invested another $30 million, bringing the total f... |
| 15.08.2024 | Invus invests additional $30M in Knime |
KNIME helps everybody make sense of data. Its free and open-source KNIME Analytics Platform enables anyone – from business to technical and data backgrounds – to intuitively work with data. KNIME Hub is the commercial complement to KNIME A... |
| 13.08.2024 | Takeda, Roche, and Genentech Recognized by the Healthcare Businesswomen's Association for Advancing Women in the Workplace Initiatives | UCB Transformational Program Also Honored
FAIRFIELD, N.J., Aug. 13, 2024 /PRNewswire/ -- To showcase the impactful commitment and outcomes of equitable practices for women in the workplace, the Healthcare Businesswomen's Association (HBA) t... |
| 07.08.2024 | KNIME's Bold Leap into the Future of AI Governance | In the fast-paced world of artificial intelligence, the race is on. Companies are scrambling to harness the power of AI while managing its risks. KNIME, a leader in open-source data science, has just made a significant move. The company sec... |
| 06.08.2024 | KNIME Secures Investment to Accelerate Enterprise AI Governance and ModelOps | KNIME, one of the leading open-source data science and AI companies, has raised additional funding from its longstanding investor Invus. Since the last announcement, Invus invested another $30M, bringing total funding to $50M. This will all... |
| 06.08.2024 | Open-source data science platform Knime raises $30M to seize opportunity in generative AI
Your vote of support is important to us and it helps us keep the content FREE.
One click below supports our mi... | Open-source data science platform provider Knime AG said today it has closed on a new, $30 million investment from its longtime backer Invus.
The round is the first major investment the company has received since Invus led its initial Serie... |
| 05.08.2024 | SITC Announces 2024 Class of Fellows to the Academy of Immuno-Oncology | Academy of Immuno-Oncology
The Society for Immunotherapy of Cancer (SITC) announces the 2024 Class of Fellows of the Academy of Immuno-Oncology (FAIO). The luminaries of the 2024 class will be inducted at an event during SITC's 39th Annual ... |
| 01.08.2024 | Curis Provides Second Quarter 2024 Financial and Operating Update | EC Grants ODD to emavusertib in PCNSL
Management to host conference call and webcast today at 8:30 a.m. ET
LEXINGTON, Mass., Aug. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emav... |
| 30.07.2024 | European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) | Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept, and robust retinal drying with VabysmoAdditional submitted ... |
| 29.07.2024 | Predicta Biosciences: Pioneering a New Era in Cancer Diagnostics | Predicta Biosciences is making waves in the ocean of cancer diagnostics. With a fresh infusion of $5.2 million in seed funding, this Boston-based precision oncology company is poised to change the landscape of how we detect and treat blood ... |
| 29.07.2024 | Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care | The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances.LumiraDx’s transformative Point of Care solution will complement Roche’s diagnostics portfolio across Clinical Chemistry, Immun... |
| 27.07.2024 | The Future of Diagnostics: Roche's Vision Unveiled at ADLM 2024 | In the bustling heart of Chicago, Roche is setting the stage for the future of laboratory diagnostics. At the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Clinical Lab Expo, the company is showcasing a suite of innovati... |
| 27.07.2024 | The Future of Brain Health: Innovations and Leadership in Alzheimer's and Multiple Sclerosis Treatments | In the ever-evolving landscape of biotechnology, two companies are making waves in the treatment of chronic neurological diseases: Immunic, Inc. and Neurophet. Both are leveraging advanced technologies and seasoned leadership to tackle the ... |
| 27.07.2024 | Predicta Biosciences Raises $5.2 Million To Develop Novel Diagnostic And Therapeutic Products | Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, announced it had raised an oversubscribed $5.2 million seed round led by The Engine Ventures. And additional participating investors in... |
| 25.07.2024 | Roche showcases solutions for laboratories of the future at the Association for Diagnostics & Laboratory Medicine 2024 Clinical Lab Expo | Roche will unveil the next generation of core lab and molecular systems, including a total solution for clinical mass spectrometry.
Attendees can experience firsthand how fully integrated systems and data solutions can streamline lab operat... |
| 25.07.2024 | Arizona Retina Surgeon Performs First FDA Approved Procedure in the U.S. That Eliminates Monthly Eye Injections for Wet AMD | Dr. Graff and Surgical Staff - First FDA-Approved Procedure in the U.S. using Susvimo® That Eliminates Monthly Eye Injections for Wet AMD
New Wet Age-Related Macular Degeneration (AMD) treatment available at Barnet Dulaney Perkins Eye Cente... |
| 25.07.2024 | [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised | Group sales were up by 5%1 at constant exchange rates (CER) (stable in CHF) in the first half, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8%
Group sales growth a... |
| 24.07.2024 | Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec | – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience –
– Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevu... |
| 23.07.2024 | Cleo's Family Health Index™ Achieves Validation from Validation Institute, Enabling Employers to Better Measure the Impact of Offering Parenting & Caregiving Benefits | Cleo's Family Health Index™ (FHI) has been validated by Validation Institute
Validation Institute finds that Cleo, the leading global comprehensive family care platform, accurately measures and assesses employee caregiver health — and there... |
| 22.07.2024 | Society for Immunotherapy of Cancer Announces Annual Award Recipients | Society for Immunotherapy of Cancer logo
The Society for Immunotherapy of Cancer (SITC) honors notable contributors to the cancer immunotherapy field each year. SITC is thrilled to announce its 2024 Annual Awards recipients who will be hono... |
| 10.07.2024 | BOLDEN THERAPEUTICS TO PRESENT AT THE 4TH ANNUAL OLIGONUCLEOTIDES FOR CNS SUMMIT | PROVIDENCE, R.I., July 10, 2024 /PRNewswire/ -- Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced their invitation... |
| 09.07.2024 | Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes | The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate1 real-time glucose values for adults living with type 1 and type 2 diabetes on flexible insulin therapy.The built-in AI-trained algorithms will empower users to proactively... |
| 08.07.2024 | Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) | The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeksSusvimo offers the first alternative to regular eye injections that are standard of care for nAMD, which imp... |
| 28.06.2024 | CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition | If approved, PiaSky will be the first monthly subcutaneous (SC) treatment for paroxysmal nocturnal haemoglobinuria (PNH) in the EU Additionally, with the option to self-administer, PiaSky may provide an alternative to existing intravenous (... |
| 28.06.2024 | Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) | Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show early and sustained vision improvements, which are non-inferior to aflibercept If approved, Vabysmo would be the f... |
| 25.06.2024 | Black and Hispanic Patients Face Higher Liver Cancer ED Visits, Study Finds | What You Should Know:
– A new study by Inovalon, a leader in healthcare data analytics, sheds light on racial and socioeconomic disparities in emergency department (ED) visits for patients with hepatocellular carcinoma (HCC), the most commo... |
| 24.06.2024 | Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories | The cobas® c 703 and cobas® ISE neo analytical units, deliver higher testing capacity and increased automation helping to improve laboratory workflows and advance patient care.The new cobas c 703 analytical unit offers industry-leading high... |
| 20.06.2024 | Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma | The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2The test helps differentiate a... |
| 15.06.2024 | Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma | The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy1
This Columvi combinat... |
| 12.06.2024 | Инсулин. Как ГМО спасает миллионы жизней | Инсулин, незаменимый медикамент для 4,6-9 миллионов россиян, по официальным данным. Уже почти 50 лет, благодаря технологиям редактирования генома, он доступен практически каждому диабетику. И позволяет им жить практически нормальной жизнью.... |
| 11.06.2024 | QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors | Industry veteran Williamson brings nearly three decades' experience as a leader in neuroscience R&D at organizations including Eli Lilly and Company, Lundbeck, Parexel, and Acadia Pharmaceuticals
Former Karuna CFO Brown brings more than... |
| 10.06.2024 | European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer | European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people ... |
| 10.06.2024 | Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization | The test uses highly sensitive PCR technology, requiring only a single nasal-swab sample to provide rapid, accurate qualitative detection and differentiation among four of the most prevalent respiratory viruses for which differential diagno... |
| 03.06.2024 | Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi® (bevacizumab), a Biosimilar Referencing Avastin® | CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing Avzivi® to the reference product Avastin®
GUANGZHOU, China, June 3, 2024 /PRNewswire/ -- Bio-Thera Solutions Inc. (688177:SH), a commerc... |
| 23.05.2024 | Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement | SYDNEY, May 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum B... |
| 20.05.2024 | SynBioBeta 2024: From novel hosts to ‘tricking’ cells to be more productive… addressing the ‘scale-cost paradox’ in biomanufacturing | Since insulin produced by genetically engineered bacteria—rather than the pancreases of slaughtered animals—was first approved in 1982, the market for ‘biomanufactured’ products produced by microbial, animal, or plant cells has grown rapidl... |
| 18.05.2024 | Детская деменция: что о ней известно, как она возникает и можно ли ее вылечить | «Детство» и «деменция» — два слова, которые не хочется употреблять вместе. Но только в Австралии около 1,4 тыс. детей и подростков живут с детским слабоумием, которое не поддается лечению. Хотя причины этого заболевания отличаются от деменц... |
| 16.05.2024 | Learning culture fosters business success, per this Houston expert | Employee training is often seen as synonymous with learning and development, but there are significant differences. Understanding the differences can help elevate your organization’s programs and foster a learning culture.
Training teaches ... |
| 07.05.2024 | Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C. | Prevent Blindness to host the 2024 ASPECT Patient Engagement and Advocacy Summit and Eyes on Capitol Hill event in Washington, D.C., May 14-16, 2024.
Three-day event brings together patients, care partners, and public health champions to ad... |
| 21.03.2024 | PocketHealth secures $33M for patient-facing medical records platform | Photo: Luis Alvarez/Getty Images
PocketHealth, a platform that enables patients to access their medical imaging, announced it secured $33 million in an all-equity Series B funding round led by Round13 Capital.
Deloitte Ventures participated... |
| 20.03.2024 | Health for All Innovator Sylvie Leotin to Give Keynote Address at the National Institutes of Health Clinical Center | Sylvie Leotin, CEO Equify Health
Sylvie Leotin
Leotin to speak on humanizing healthcare disparities. She founded Equify Health after surviving cancer to improve healthcare delivery for everyone.
If we want to achieve health equity, we need ... |
| 11.03.2024 | Ribometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting | — Data demonstrate in vivo tumor regression via RNA-binding protein inhibitor targeting eIF4E in multiple tumor types with significant unmet need —
— First data disclosure from the Company’s RNA-targeting small molecule platform and its pro... |
| 06.03.2024 | Global Bevacizumab Biosimilars Market Outlook 2024-2028 & 2033 Featuring Cipla, Reliance Lifesciences, Genentech, Fujifilm Kyowa Kirin Biologics, and Pfizer | - |
| 04.03.2024 | Head and Neck Cancer Market Size, Trends, Industry Statistics and Latest Insights Till 2034 | BROOKLYN, NY, USA, March 4, 2024 /EINPresswire.com/ -- What is the market for head and neck cancer?
The head and neck cancer market reached a value of US$ 3,252.3 Million in 2023 and expected to reach US$ 7,279.8 Million by 2034, exhibiting... |
| 21.11.2023 | Nvidia collaborates with Genentech to accelerate AI-driven drug discovery | Are you ready to bring more awareness to your brand? Consider becoming a sponsor for The AI Impact Tour. Learn more about the opportunities here.
Nvidia is working with Roche Group’s Genentech to help the company pioneer the use of generati... |
| 21.11.2023 | Genentech, NVIDIA Partner to Revolutionize Drug Discovery with AI | What You Should Know:
– Genentech and NVIDIA today announced a multi-year strategic research collaboration that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research experti... |
| 17.08.2023 | The 30 young leaders who are forging a new future for the healthcare industry in 2023 | Your browser does not support the video element. This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
A new generation of leaders is transforming the healthcare industry.
They're developing ne... |
| 20.07.2023 | Stanford president resigns following research ethics probe | The president of Stanford University has stepped down in the wake of an independent investigation that found “substandard practices” in research papers he was involved in.
Marc Tessier-Lavigne, the leader of the prestigious California unive... |
| 27.06.2023 | Rare Disease Patient Advocates Gather in San Diego for a Week of Events to Connect, Learn, and Empower | Week in RARE events "We are creating an unparalleled opportunity for rare disease advocates to engage with each other, build relationships, and help them understand what they can do to change what it means to live with a rare disease d... |
| 27.06.2023 | Nvidia backs Flywheel in $54M round to accelerate medical AI development | Join top executives in San Francisco on July 11-12, to hear how leaders are integrating and optimizing AI investments for success. Learn More
Hours after teaming up with data cloud major Snowflake, Nvidia has backed a vendor working to over... |
| 08.06.2023 | Letter of Support (LOS) Initiative | Critical Path Institute's (C-Path) Predictive Safety Testing Consortium (PSTC), Nephrotoxicity Working Group (NWG) Urinary Biomarkers: Osteopontin and Neutrophil Gelatinase-associated Lipocalin (NGAL) Early Clinical Drug Development 8/20/20... |
| 01.06.2023 | Top AI researcher dismisses AI ‘extinction’ fears, challenges ‘hero scientist’ narrative | Join top executives in San Francisco on July 11-12, to hear how leaders are integrating and optimizing AI investments for success. Learn More
Kyunghyun Cho, a prominent AI researcher and an associate professor at New York University, has ex... |
| 31.05.2023 | Equify Health Receives $1 Million Grant to Launch Transformative Education Workshop to Accelerate Health Care Equity | "Current diversity training doesn’t focus on the patient experience. That’s what makes our workshop unique. We allow medical providers to see firsthand what marginalized patients go through and discover for themselves how health care f... |
| 06.04.2023 | Genentech review of Tessier-Lavigne paper finds no evidence of fraud — but hints at a different misconduct case | South San Francisco biotech Genentech on Thursday announced that an internal review of misconduct allegations concerning a landmark 2009 paper co-authored by Marc Tessier-Lavigne, a former top executive at the company and Stanford Universit... |
| 15.02.2023 | Mindful Life Project raises $1.65 million to address America’s youth mental health crisis by expanding its innovative model in California schools | Students practice mindfulness in school. “Schools become places of belonging, compassion, and wellness when students and educators practice mindfulness, which in turn creates a strong foundation that prioritizes mental health,” says Mindful... |
| 09.01.2023 | Healthcare Hires of Note | ProofPilot, a digital protocol automation platform for clinical trials, has added Bernadette Tosti to its executive leadership team in the role of chief product officer this week. Tosti has more than 15 years of experience in the digital cl... |
| 23.12.2022 | Pharmalittle: FDA approves a Genentech blood-cancer drug; Sean Parker expands his immunotherapy research empire | Good morning, Pharmalittle family! Your loyal scribe Ed Silverman is taking today off, so he bestowed upon me, Adam Feuerstein, the great honor of delivering today’s roundup of pharma news. But first, my coffee: Intelligentsia House Blend, ... |
| 02.11.2022 | Prevent Blindness Revamps, Expands its “Living Well With Low Vision” Online Resource | Prevent Blindness unveils newly re-designed, updated Living Well With Low Vision online resource. “Today we are proud to offer our newly expanded resource to provide patients with the necessary information they need to live their most fulfi... |
| 24.10.2022 | Roche receives FDA clearance for COVID-19 PCR test for use on cobas 6800/8800 Systems | The cobas SARS-CoV-2 Qualitative test is one of the first COVID-19 PCR tests performed on an automated, high throughput platform to receive FDA 510(k) clearance.
This FDA clearance will ensure that the healthcare community has access to tim... |
| 19.10.2022 | Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022 | OCREVUS data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS)Largest pregnancy safety data across anti-CD20 medicines for OC... |
| 14.10.2022 | Taking Charge of a Cancer Diagnosis With Biomarker Testing | (BPT) - David was in his thirties and living a healthy life when doctors discovered a cancerous mass in his neck. He began treatment immediately, unsure about the journey ahead, and after enduring several therapies that left him feeling wor... |
| 12.10.2022 | Roche to introduce its next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”) under CE Mark for self-test and professional use | Broad and trusted portfolio of COVID-19 rapid tests feature innovative updates and enhanced performance, building on insights gained throughout the pandemicAll tests now work seamlessly with navify® Pass, Roche’s digital solution that allow... |
| 12.10.2022 | Positive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA) | New two-year Evrysdi data show improvement or maintenance of motor function in people with SMA, a progressive neuromuscular disease that can be fatal The JEWELFISH study enrolled the broadest and most diverse patient population ever studied... |
| 11.10.2022 | Roche launches PRAME (EPR20330) Antibody to identify PRAME protein expression in patients that may have melanoma | The PRAME (EPR20330) Antibody evaluates PRAME protein expression from patients with suspected melanoma. Understanding if the PRAME protein is expressed helps enable more informed clinical decisions and may improve patient outcomes.The PRAME... |
| 05.10.2022 | Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022 | New positive data from Evrysdi, a treatment for spinal muscular atrophy (SMA), a progressive neuromuscular disease that can be fatalData from the gene therapy programme for Duchenne muscular dystrophy (DMD), a progressive disease that leads... |
| 04.10.2022 | Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU | Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2. These patients with HER2 low status may now be eligible for a targeted treatment, which could significantly improve their outcomes.1,2The PAT... |
| 19.09.2022 | European Commission approves Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss | Phase III data that showed people with nAMD and DME treated with Vabysmo up to every four months achieved similar outcomes compared to receiving treatment every two months with aflibercept In addition, patients treated with Vabysmo received... |
| 23.08.2022 | Roche launches a digital PCR system, a powerful new diagnostics platform in the fight against cancer and other diseases | The Digital LightCycler System is a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient’s cancer, genetic disease or infection.The new system has the potential to find and quantify ul... |
| 16.08.2022 | FDA accepts supplemental Biologics License Application for Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma | First new treatment regimen in more than 20 years to significantly improve outcomes in people with this fast-growing type of lymphoma
Application is based on pivotal data from the phase III POLARIX study showing Polivy plus R-CHP significan... |
| 12.08.2022 | Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older | Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age The FDA also approved Xofluza to prevent influenza in children aged five years and ol... |
| 22.07.2022 | CHMP recommends EU approval of Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss | Vabysmo (faricimab) simultaneously targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME)The CHMP recommendation is based on results across four pha... |
| 19.07.2022 | Roche's Elecsys Amyloid Plasma Panel granted FDA Breakthrough Device Designation to enable a timely diagnosis of Alzheimer’s disease | The Elecsys Amyloid Plasma Panel is intended to be used in conjunction with other clinical information in symptomatic patients who are being evaluated for Alzheimer's disease and other causes of cognitive decline.The Elecsys Amyloid Plasma ... |
| 18.07.2022 | Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus | Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.The Elecsys HCV Duo immunoassay enables significantly earl... |
| 14.07.2022 | New two-year data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration | In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two years. This represents an increase from 45% at year one Patients treated with Vabysmo received a median number of 10 injections o... |
| 11.07.2022 | New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A | Hemlibra continues to demonstrate clinically meaningful bleed control, with 66.7% of participants with moderate or mild haemophilia A experiencing zero treated bleeds at 55.6 weeks median follow-up [1]New data also reinforce Hemlibra’s favo... |
| 06.07.2022 | FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular lymphoma | Lunsumio® (mosunetuzumab) could be the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma Application is based on results from the pivotal phase I/II study showing Lu... |
| 28.06.2022 | Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics | The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s treatment.
Cancer is a leading cause of death world... |
| 17.06.2022 | New Alzheimer Disease Drug Delivers Disappointing Results | FRIDAY, June 17, 2022 (HealthDay News) -- An experimental drug for Alzheimer disease called crenezumab did not prevent or slow mental decline in patients with a genetic mutation that greatly raises the risk for developing the disease, the r... |
| 17.06.2022 | New Alzheimer's Drug Delivers Disappointing Results | FRIDAY, June 17, 2022 (HealthDay News) -- An experimental Alzheimer's drug called crenezumab did not prevent or slow mental decline in patients with a genetic mutation that greatly raises the risk of developing the disease, the results of a... |
| 16.06.2022 | Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options | Every year, over 604,000 women worldwide are diagnosed with cervical cancer and approximately 342,000 die from this preventable disease, caused by infection with Human Papillomavirus (HPV). 1Nearly nine out of 10 women who die from cervical... |
| 15.06.2022 | Roche receives FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and quantitatively measure viral load levels of COVID-19 | The cobas SARS-CoV-2 Duo test combines the standard qualitative result of a traditional SARS-CoV-2 PCR test with a quantitative result, which measures the viral load of a patient suspected of COVID-19.Potential benefits of the cobas SARS-Co... |
| 10.06.2022 | Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting | Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their fi... |
| 09.06.2022 | European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer | In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the first and only cancer... |
| 31.05.2022 | FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA) | Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk Prescribing information updated with FIREFISH data showing the majority of symptomatic ... |
| 27.05.2022 | New pivotal data demonstrate clinical benefit of Roche’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma | Data to be presented for the first time at ASCO and EHA 2022 show glofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma 1Glofitamab has the potential to offer a readily ... |
| 25.05.2022 | Roche’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma | First new treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival is approved for people with previously untreated diffuse large B-cell lymphoma (DLBCL)Approval is based on pivotal dat... |
| 12.05.2022 | Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure | Almost half of the world’s population has no or limited access to diagnosticsThis situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of in... |
| 11.05.2022 | [Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer | The SKYSCRAPER-01 study evaluating tiragolumab plus Tecentriq did not meet its co-primary endpoint of progression-free survivalThe other co-primary endpoint of overall survival was immature and the study will continue until the next planned... |
| 29.04.2022 | New three-year data for Roche’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) | 91% of infants treated with Evrysdi in the FIREFISH study were still alive at three years Infants treated with Evrysdi maintained or continued to improve in measures of motor function, including their ability to sit without support for 5 an... |
| 29.04.2022 | UPDATED: Roche releases more Evrysdi data leading up to FDA decision for very young infants with SMA | One month away from an FDA decision on Evrysdi for infants under two months old, Roche’s Genentech has released new long-term data on its oral drug for spinal muscular atrophy (SMA).
Dalia Moawad
The data show that, after thre... |
| 22.04.2022 | CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer | In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive careMore than half of people with early-stage... |
